Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Newborn body composition after maternal bariatric surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cytomegalovirus-specific CD8+ T-cell responses are associated with arterial blood pressure in people living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Exposure to Air Pollution and Incidence of Myocardial Infarction: A Danish Nurse Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evaluation of computed tomography myocardial perfusion in women with angina and no obstructive coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Studies have suggested a beneficial effect of angiotensin-converting enzyme (ACE) inhibition. To explore whether the ACE inhibitor ramipril has a direct effect on the microvasculature beyond the blood pressure (BP) lowering effect, we investigated whether ramipril improved coronary microvascular function in normotensive women with coronary microvascular dysfunction (CMD).

METHODS: We included 63 normotensive women with angina, no epicardial stenosis>50% and CMD defined as a coronary flow velocity reserve (CFVR)<2.2 assessed by adenosine stress-echocardiography in a randomized double-blinded, superiority trial with 1:1 allocation to placebo or ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks. Primary outcome was CFVR. Secondary outcomes were left ventricular systolic and diastolic function and symptoms evaluated by Seattle Angina Questionnaire (clinicaltrials.gov, NCT02525081).

RESULTS: Follow-up was available on 55 patients. BP remained unchanged during treatment in both groups. CFVR improved in both the ramipril (p = 0.004) and placebo group (p = 0.026) with no difference between groups (p = 0.63). Symptoms improved in both groups with no significant between-group differences. No changes were detected in parameters of systolic and diastolic function. No serious adverse reactions were reported.

CONCLUSIONS: In normotensive women with angina and CMD, treatment with ramipril had no significant effect on CFVR or symptoms compared with placebo. The effect of ACE inhibition previously reported may be mediated by blood pressure reduction.

Original languageEnglish
JournalPLoS One
Volume13
Issue number6
Pages (from-to)e0196962
ISSN1932-6203
DOIs
Publication statusPublished - 8 Jun 2018

    Research areas

  • Aged, Angiotensin-Converting Enzyme Inhibitors/administration & dosage, Blood Flow Velocity/drug effects, Blood Pressure/drug effects, Coronary Circulation/drug effects, Double-Blind Method, Female, Follow-Up Studies, Humans, Microcirculation/drug effects, Microvascular Angina/drug therapy, Middle Aged, Ramipril/administration & dosage

ID: 55741349